Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients

Lancet

Volumn 350, Issue 9086, 1997, Pages 1193-1198

  Nashan, Björn ^a   Moore, Richard ^c   Amlot, Peter ^b   Schmidt, Albrecht Georg ^d   Abeywickrama, Kamal ^d   Soulillou, Jean Paul ^e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c Cardiff Royal Infirmary   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Inst Transplant/Rech Transplant   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CADAVER; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TIME;

ACUTE DISEASE; ADULT; AGED; ANTIBODIES, MONOCLONAL; CADAVER; CYCLOSPORINE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; TIME FACTORS;

EID: 0031586439     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)09278-7     Document Type: Article

References (36)

1. Gulanikar AC, MacDonald AS, Sungurtekin U, Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992; 53: 323-28.
2. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993-95.
3. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57: 857-59.
4. Nelson PW, Cosimi AB, Delmonica FL, et al. Anti-thymocyte globulin as the primary treatment for renal allograft rejection. Transplantation 1983; 36: 587-89.
5. Ortho Multicentre Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for the rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337-42.
6. Soulillou JP. Relevant targets for therapy with monoclonal antibodies in allograft transplantation. Kidney Int 1994; 46: 540-53.
7. Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175-82.
8. Soulillou JP, Le Mauff B, Olive D, et al. Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin 2. Lancet 1987; i: 1339-42.
9. Kupiec-Weglinski JW, Diamantstein T, Tilney NL. Interleukin 2 receptor-targeted therapy - rationale and applications in organ transplantation. Transplantation 1988; 46: 785-92.
10. Morgan DA, Ruscetti FW, Gallo RC. Selective in vitro growth of T-lymphocytes from normal human bone marrow. Science 1976; 193: 1007-08.
11. Amlot PL, Tahami F, Chinn D, Rawlings E. Activation antigen expression on human T cells. I. Analysis by two-colour flow cytometry of umbilical cord blood, adult blood and lymphoid tissue. Clin Exp Immunol 1996; 105: 176-82.
12. Nashan B, Schwinzer R, Schlitt H, Wonigeit K, Pichlmayr R. Immunological effects of the anti-IL-2 receptor monoclonal antibody BT 563 in liver allografted patients. Transplant Immunol 1995; 3: 203-11.
13. Robb RJ, Greene WC, Rusk CM. Low and high affinity cellular receptors for interleukin 2: implications for the level of Tac antigen. J Exp Med 1984; 160: 1126-46.
14. Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Ythier A, Strom TB. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med 1985; 162: 358-62.
15. Kupiec-Weglinski JW, Diamantstein T, Tilney NL, Strom TB. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci USA 1986; 83: 2624-27.
16. Kirkman RL, Shapiro ME, Carpenter CR, et al. A randomised prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107-13.
17. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748-55.
18. Nashan B, Schlitt HJ, Schwinzer R, et al. Immunoprophyl axis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients. Transplantation 1996; 61: 546-54.
19. Amlot PL. The clinical and experimental use of monoclonal antibodies to the IL-2 receptor. In: Chatenoud L, ed. Monoclonal antibodies in transplantation. Austin, Texas: R G Landes, 1995: 53-98.
20. Khazaeli MB, Saleh MN, Liu T, Kaladas PM, Gilman SC, LoBuglio AF. Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody. J Clin Immunol 1992; 12: 116-21.
21. Meredith R, Khazaeli M, Plott E, et al. Comparison of two mouse/human chimeric antibodies in patients with metastatic colon cancer. Antibody Immunoconj Radiopharm 1992; 5: 75-80.
22. Kovarik JM, Rawlings E, Sweny P, et al. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD 25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proc 1996; 28: 913-14.
23. Anonymous. Good clinical practice for trials on medicinal products in the European Community. Brussels, Belgium: CPMP Working Party on Safety of Medicinal Products, 1990.
24. Anonymous. Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects. Helsinki, amended Tokyo 1975, Venice 1983, Hong Kong 1989. Ferney-Voltaire, France: World Medical Association, 1964.
25. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-22.
26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
27. Hardie IR, on behalf of the Zenapax Dual Therapy Study Group. A randomized clinical trial of Zenapax for preventing acute rejection in renal transplantation (abstr). Nephrology 1997; 3:(220) S71.
28. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-25.
29. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-32.
30. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-37.
31. Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm 1995; 52: 1521-35.
32. Deschler DG, Osorio R, Ascher NL, Lee KC. Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression. Arch Otolaryngol Head Neck Surg 1995; 121: 1037-41.
33. Furth S, Neu A, Colombani P, Plotnick L, Turner ME, Fivush B. Diabetes as a complication of tacrolimus (FK 506) in pediatric renal transplant patients. Pediatr Nephrol 1996; 10: 64-6.
34. Ishii N, Takeshita T, Kimura Y, et al. Expression of the IL-2 receptor γ chain on various populations in human peripheral blood. Int Immunol 1994; 6: 1273-77.
35. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988; 25: 367-472.
36. Nalesnik MA. Lymphoproliferative disease in organ transplant recipients. Springer Semin Immunopathol 1991; 13: 199-216.